Premium
EBV Specific CTL: A Model for Immune Therapy
Author(s) -
Rooney C.M.,
Heslop H.E.,
Brenner M.K.
Publication year - 1998
Publication title -
vox sanguinis
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 0.68
H-Index - 83
eISSN - 1423-0410
pISSN - 0042-9007
DOI - 10.1111/j.1423-0410.1998.tb05463.x
Subject(s) - ctl* , cytotoxic t cell , immune system , lymphoma , virus , immunology , virology , viral vector , biology , medicine , cancer research , in vitro , cd8 , genetics , gene , recombinant dna
We have been generating Epstein‐Barr virus specific cytotoxic T cells for patients at high risk of developing EBV driven lymphoma. To discover the fate of the cells in vivo, we first marked them genetically, using a retroviral vector. Our results in 51 patients show that the approach is safe, that the CTL persist for several years and that they are able to mediate anti‐viral and anti‐tumor effects. We are now studying other virally‐linked malignancies to discover whether a similar approach will be of therapeutic value.